Categories Earnings, Health Care

Mallinckrodt’s stock soars 12% on Q4 results beat

Mallinckrodt plc (MNK) topped market expectations on revenue and earnings for the fourth quarter of 2018, sending the shares soaring 12.9% in premarket hours on Tuesday.

Net sales grew 5.4% to $834.9 million from the same period last year. On a constant-currency basis, sales growth was 5.6%.

On a GAAP basis, the company reported a net loss of $3.7 billion, or $44.64 per share, compared to a net income of $1.6 billion, or $17.41 per share, in the prior-year period, mainly due to a non-cash goodwill impairment charge. Adjusted EPS improved 8.5% year-over-year to $2.18.

Mallinckrodt stated that the Specialty Generics Disposal Group, which was previously classified in discontinued operations, has been recast to continuing operations and the company now operates two reportable segments – the Specialty Brands segment and the Specialty Generics and Amitiza segment.

During the quarter, sales in the Specialty Brands segment totaled $586.5 million. INOMAX and OFIRMEV posted sales increases of 10.4% and 11.8% respectively, helped by strong demand and execution.

Mallinckrodt soars 10% on strong Q3

Net sales for HP Acthar Gel dropped 4.1% as the brand continues to tackle patient withdrawal issues and growing payer scrutiny on overall specialty pharmaceutical spending. Therakos net sales dipped slightly to $57 million in the quarter.

Also see: Mallinckrodt Q4 2018 Earnings Conference Call Transcript

In the Specialty Generics and Amitiza segment, net sales grew 23.8% to $248.4 million, mainly due to the inclusion of AMITIZA in early 2018. Excluding AMITIZA, net sales of the other Specialty Generics products dropped 8.4%. Mallinckrodt expects these declines to moderate and the segment to return to growth in 2019.

For the full year of 2019, Mallinckrodt expects adjusted EPS of $8.10 to $8.40. Total net sales for both the Specialty Brands and Specialty Generics and Amitiza segments are expected to increase 1-4%.


Get access to timely and accurate verbatim transcripts that are published within hours of the event.

Most Popular

Should investors worry about Micron’s (MU) weak Q4 results and guidance?

The semiconductor industry is a rapidly growing business segment that currently thrives on the digital transformation wave. The demand for memory chips and other semiconductor products increased over the years,

What has Bed Bath & Beyond (BBBY) outlined for this fiscal year?

Shares of Bed Bath & Beyond (NASDAQ: BBBY) were up on Friday, a day after the company delivered disappointing results for the second quarter of 2022. The company reported a

NKE Earnings: Highlights of Nike’s Q1 2023 results

Nike, Inc. (NYSE: NKE) has reported a decrease in net profit for the first quarter of 2023, despite a modest increase in revenues. The company's stock suffered a big loss

Add Comment
Viewing Highlight